arthroplasty"[tw] OR "knee arthroplasty"[tw] OR "hip replacements"[tw] OR "knee replacements"[tw] OR "hip arthroplasties"[tw] OR "knee arthroplasties"[tw] OR "TJA"[tw] OR "TKA"[tw] OR "THA"[tw] OR "joint replacement"[tw] OR "joint arthroplasty"[tw] OR "TKR"[tw] OR "TJR"[tw] OR "THR"[tw] OR "lower limb arthroplasty"[tw] OR "lower limb arthroplasties"[tw] OR "lower extremity arthroplasty"[tw] OR "lower extremity arthroplasties"[tw] OR "lower limb joint replacement"[tw] OR "lower limb joint replacements"[tw] OR "lower extremity joint replacement"[tw] OR "lower extremity joint replacements"[tw] OR orthopedic*[tw] OR orthopaedic*[tw] OR acetabuloplast*[tw] OR (("lower limb"[tw] OR "lower extremity"[tw] OR "lower extremities"[tw] OR "hip"[tw] OR "knee"[tw] OR "joint"[tw] OR "joints"[tw]) AND ("replacement"[tw] OR "replacements"[tw] OR "arthroplasty"[tw] OR "arthroplasties"[tw])))
A multi-site, masked, randomised parallel group study employing a double dummy treatment design was performed in canine veterinary patients to determine the comparative efficacy and safety of mavacoxib and carprofen in the treatment of pain and inflammation associated with osteoarthritis for a period of 134 days. Treatments were administered according to their respective summaries of product characteristics. Of 139 dogs screened, 124 were suitable for study participation: 62 of which were dosed with mavacoxib and 62 with carprofen. Both treatments resulted in a very similar pattern of considerable improvement as indicated in all parameters assessed by both owner and veterinarian. The primary efficacy endpoint ‘overall improvement’ was a composite score of owner assessments after approximately six weeks of treatment. Both drugs were remarkably effective, with 57/61 (93.4 per cent) of mavacoxib-treated dogs and 49/55 (89.1 per cent) of carprofen-treated dogs demonstrating overall improvement and with mavacoxib's efficacy being non-inferior to carprofen. The treatments had a similar safety profile as evidenced by documented adverse events and summaries of clinical pathology parameters. The positive clinical response to treatment along with the safety and dosing regimen of mavacoxib makes it an attractive therapy for canine osteoarthritis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.